FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

John Isaacs

Research Profile

Disorders

Living Beings

Anatomy

Chemicals & Drugs

Physiology

Cell Divisions

Procedures

Orchiectomy

Co-author Network

Publications

TOP 3
John T Isaacs; Sushant Kachhap; Lizamma Antony; Anders Björk; Per Björk; W Nathaniel Brennen; Susan L Dalrymple; Stephanie Gerber; Hans-Joerg Hammers; Jun Luo; Anders Olsson; Michel Wissing; Li Xing; Tomas Leanderson
Tasquinimod Is an Allosteric Modulator of HDAC4 survival signaling within the compromised cancer microenvironment.
W Nathaniel Brennen; Shuangling Chen; Samuel R Denmeade; John T Isaacs
Quantification of Mesenchymal Stem Cells (MSCs) at sites of human prostate cancer.
John T Isaacs; Jun Luo; Georges H Ndikuyeze; Lizamma Antony; Shuangling Chen; Susan P Dalrymple; Jason M D'Antonio; Samuel R Denmeade
Adaptive auto-regulation of androgen receptor provides a paradigm shifting rationale for bipolar androgen therapy (BAT) for castrate resistant human prostate cancer.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of John Isaacs (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: John T Isaacs; Sushant Kachhap; Lizamma Antony; Anders Björk; Per Björk; W Nathaniel Brennen; Susan L Dalrymple; Stephanie Gerber; Hans-Joerg Hammers; Jun Luo; Anders Olsson; Michel Wissing; Li Xing; Tomas Leanderson
Tasquinimod Is an Allosteric Modulator of HDAC4 survival signaling within the compromised cancer microenvironment.
Cancer research 2013;73(4):1386-99.
2013: W Nathaniel Brennen; Shuangling Chen; Samuel R Denmeade; John T Isaacs
Quantification of Mesenchymal Stem Cells (MSCs) at sites of human prostate cancer.
Oncotarget 2013;4(1):106-17.
2012: John T Isaacs; Jun Luo; Georges H Ndikuyeze; Lizamma Antony; Shuangling Chen; Susan P Dalrymple; Jason M D'Antonio; Samuel R Denmeade
Adaptive auto-regulation of androgen receptor provides a paradigm shifting rationale for bipolar androgen therapy (BAT) for castrate resistant human prostate cancer.
The Prostate 2012;72(14):1491-505.
2012: Shuangling Chen; Lorenzo Principessa; John T Isaacs
Human prostate cancer initiating cells isolated directly from localized cancer do not form prostaspheres in primary culture.
The Prostate 2012;72(13):1478-89.
2012: W Nathaniel Brennen; John T Isaacs; D Marc Rosen; Hao Wang; Samuel R Denmeade
Targeting carcinoma-associated fibroblasts within the tumor stroma with a fibroblast activation protein-activated prodrug.
Journal of the National Cancer Institute 2012;104(17):1320-34.
2012: Samuel R Denmeade; John T Isaacs
Engineering enzymatically activated "molecular grenades" for cancer.
Oncotarget 2012;3(7):666-7.
2012: Samuel R Denmeade; Craig Dionne; Bora Gurel; W Nathaniel Brennen; Michael A Carducci; S Brøgger Christensen; Ingrid Dach; Susan L Dalrymple; Angelo M DeMarzo; Annastasiah Mhaka; Jesper V Møller; Poul Nissen; Claus Olesen; D Marc Rosen; George Wilding; John T Isaacs
Engineering a prostate-specific membrane antigen-activated tumor endothelial cell prodrug for cancer therapy.
Science translational medicine 2012;4(140):140ra86.
2012: Susan L Dalrymple; Theodore L DeWeese; Robyn E Becker; Haoming Zhou; John T Isaacs
Tasquinimod prevents the angiogenic rebound induced by fractionated radiation resulting in an enhanced therapeutic response of prostate cancer xenografts.
The Prostate 2012;72(6):638-48.
2012: W Nathaniel Brennen; John T Isaacs; Samuel R Denmeade
Rationale behind targeting fibroblast activation protein-expressing carcinoma-associated fibroblasts as a novel chemotherapeutic strategy.
Molecular cancer therapeutics 2012;11(2):257-66.
2011: Simon A Williams; Robert J Cotter; John T Isaacs; Christine A Jelinek; Ivan Litvinov; Samuel R Denmeade
Enzymatically active prostate-specific antigen promotes growth of human prostate cancers.
The Prostate 2011;71(15):1595-607.
2011: Karen S Sfanos; John T Isaacs
The "infectious" nature of human prostate cancer: a cautionary note.
Oncotarget 2011;2(4):281-3.
2010: John T Isaacs
The long and winding road for the development of tasquinimod as an oral second-generation quinoline-3-carboxamide antiangiogenic drug for the treatment of prostate cancer.
Expert opinion on investigational drugs 2010;19(10):1235-43.
2010: Samuel R Denmeade; John T Isaacs
Bipolar androgen therapy: the rationale for rapid cycling of supraphysiologic androgen/ablation in men with castration resistant prostate cancer.
The Prostate 2010;70(14):1600-7.
2010: Simon A Williams; Yi Xu; Angelo M DeMarzo; John T Isaacs; Samuel R Denmeade
Prostate-specific antigen (PSA) is activated by KLK2 in prostate cancer ex vivo models and in prostate-targeted PSA/KLK2 double transgenic mice.
The Prostate 2010;70(7):788-96.
2010: Jason M D'Antonio; Donald J Vander Griend; Lizamma Antony; George Ndikuyeze; Susan L Dalrymple; Shahriar Koochekpour; John T Isaacs
Loss of androgen receptor-dependent growth suppression by prostate cancer cells can occur independently from acquiring oncogenic addiction to androgen receptor signaling.
PloS one 2010;5(7):e11475.
2010: Anders Olsson; Anders Björk; Johan Vallon-Christersson; John T Isaacs; Tomas Leanderson
Tasquinimod (ABR-215050), a quinoline-3-carboxamide anti-angiogenic agent, modulates the expression of thrombospondin-1 in human prostate tumors.
Molecular cancer 2010;9():107.
2010: Vander Griend Donald; Jason D'Antonio; Bora Gurel; Lizamma Antony; Angelo M DeMarzo; John T Isaacs
Cell-autonomous intracellular androgen receptor signaling drives the growth of human prostate cancer initiating cells.
The Prostate 2010;70(1):90-9.
2009: Pratap Singh; Aaron M LeBeau; Hans Lilja; Samuel R Denmeade; John T Isaacs
Molecular insights into substrate specificity of prostate specific antigen through structural modeling.
Proteins 2009;77(4):984-93.
2009: J P Michiel Sedelaar; John T Isaacs
Tissue culture media supplemented with 10% fetal calf serum contains a castrate level of testosterone.
The Prostate 2009;69(16):1724-9.
2009: Vander Griend Donald; Yuko Konishi; Angelo M DeMarzo; John T Isaacs; Alan K Meeker
Dual-label centromere and telomere FISH identifies human, rat, and mouse cell contribution to Multispecies recombinant urogenital sinus xenografts.
The Prostate 2009;69(14):1557-64.
2009: Jason M D'Antonio; Vander Griend Donald; John T Isaacs
DNA licensing as a novel androgen receptor mediated therapeutic target for prostate cancer.
Endocrine-related cancer 2009;16(2):325-32.
2009: Donald J Vander Griend; Lizamma Antony; Susan L Dalrymple; Yi Xu; S Brøgger Christensen; Samuel R Denmeade; John T Isaacs
Amino acid containing thapsigargin analogues deplete androgen receptor protein via synthesis inhibition and induce the death of prostate cancer cells.
Molecular cancer therapeutics 2009;8(5):1340-9.
2009: Junichiro Ishioka; Shuntaro Hara; John T Isaacs; Arihiro Tomura; Kiyohiro Nishikawa; Yukio Kageyama
Suppression of mutant androgen receptors by flutamide.
International journal of urology : official journal of the Japanese Urological Association 2009;16(5):516-21.
2009: Igal Madar; Yi Huang; Hayden T Ravert; Susan L Dalrymple; Nancy E Davidson; John T Isaacs; Robert F Dannals; J James Frost
Detection and quantification of the evolution dynamics of apoptosis using the PET voltage sensor 18F-fluorobenzyl triphenyl phosphonium.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2009;50(5):774-80.
2009: Aaron M LeBeau; Pratap Singh; John T Isaacs; Samuel R Denmeade
Prostate-specific antigen is a "chymotrypsin-like" serine protease with unique P1 substrate specificity.
Biochemistry 2009;48(15):3490-6.
2009: S Brøgger Christensen; Dorthe Mondrup Skytte; Samuel R Denmeade; Craig Dionne; Jesper Vuust Møller; Poul Nissen; John T Isaacs
A Trojan horse in drug development: targeting of thapsigargins towards prostate cancer cells.
Anti-cancer agents in medicinal chemistry 2009;9(3):276-94.
2009: Lochlan F Shelfer; John T Isaacs
The alchemy of Jargon: etymologies of urologic neologisms: number 1--introduction to the series.
The Prostate 2009;69(3):225-7.
2008: Vander Griend Donald; Wouter L Karthaus; Susan L Dalrymple; Alan K Meeker; Angelo M DeMarzo; John T Isaacs
The role of CD133 in normal human prostate stem cells and malignant cancer-initiating cells.
Cancer research 2008;68(23):9703-11.
2008: Pratap Singh; Gurulingappa Hallur; RAVI ANCHOORI; Oladapo Bakare; Yukio Kageyama; Saeed R Khan; John T Isaacs
Rational design of novel antiandrogens for neutralizing androgen receptor function in hormone refractory prostate cancer.
The Prostate 2008;68(14):1570-81.
2008: Wennuan Liu; Chunmei Carol Xie; Yi Zhu; Tao Li; Jielin Sun; Yu Cheng; Charles M Ewing; Sue Dalrymple; Aubrey R Turner; Jishan Sun; John T Isaacs; Bao-Li Chang; S Lilly Zheng; William B Isaacs; Jianfeng Xu
Homozygous deletions and recurrent amplifications implicate new genes involved in prostate cancer.
Neoplasia (New York, N.Y.) 2008;10(8):897-907.
2008: Aaron M LeBeau; Pratap Singh; John T Isaacs; Samuel R Denmeade
Potent and selective peptidyl boronic acid inhibitors of the serine protease prostate-specific antigen.
Chemistry & biology 2008;15(7):665-74.
2008: John T Isaacs
Prostate stem cells and benign prostatic hyperplasia.
The Prostate 2008;68(9):1025-34.
2008: Kenneth Pienta; Cory Abate-Shen; David B Agus; Ricardo M Attar; Leland W K Chung; Norman M Greenberg; William C Hahn; John T Isaacs; Nora M Navone; Donna M Peehl; Jonathon W Simons; David B Solit; Howard R Soule; Terry A VanDyke; Michael J Weber; Lily Wu; Robert L Vessella
The current state of preclinical prostate cancer animal models.
The Prostate 2008;68(6):629-39.
2008: Pratap Singh; Simon A Williams; Meha Shah; Thomas Lectka; Gareth J Pritchard; John T Isaacs; Samuel R Denmeade
Mechanistic insights into the inhibition of prostate specific antigen by beta-lactam class compounds.
Proteins 2008;70(4):1416-28.
2007: Connie Collins; Michael A Carducci; Mario A Eisenberger; John T Isaacs; Alan W Partin; Roberto Pili; Victoria Sinibaldi; JANET WALCZAK; Samuel R Denmeade
Preclinical and clinical studies with the multi-kinase inhibitor CEP-701 as treatment for prostate cancer demonstrate the inadequacy of PSA response as a primary endpoint.
Cancer biology & therapy 2007;6(9):1360-7.
2007: Srinivas K Kumar; Simon A Williams; John T Isaacs; Samuel R Denmeade; Saeed R Khan
Modulating paclitaxel bioavailability for targeting prostate cancer.
Bioorganic & medicinal chemistry 2007;15(14):4973-84.
2007: Masayasu Urushibara; Junichiro Ishioka; Nobuhiko Hyochi; Kazunori Kihara; Shuntaro Hara; Pratap Singh; John T Isaacs; Yukio Kageyama
Effects of steroidal and non-steroidal antiandrogens on wild-type and mutant androgen receptors.
The Prostate 2007;67(8):799-807.
2007: Susan L Dalrymple; Robin E Becker; John T Isaacs
The quinoline-3-carboxamide anti-angiogenic agent, tasquinimod, enhances the anti-prostate cancer efficacy of androgen ablation and taxotere without effecting serum PSA directly in human xenografts.
The Prostate 2007;67(7):790-7.
2007: Vander Griend Donald; Ivan V Litvinov; John T Isaacs
Stabilizing androgen receptor in mitosis inhibits prostate cancer proliferation.
Cell cycle (Georgetown, Tex.) 2007;6(6):647-51.
2007: Simon A Williams; Rosemina F Merchant; Elizabeth Garrett-Mayer; John T Isaacs; J Thomas Buckley; Samuel R Denmeade
A prostate-specific antigen-activated channel-forming toxin as therapy for prostatic disease.
Journal of the National Cancer Institute 2007;99(5):376-85.
2007: Simon A Williams; Pratap Singh; John T Isaacs; Samuel R Denmeade
Does PSA play a role as a promoting agent during the initiation and/or progression of prostate cancer?
The Prostate 2007;67(3):312-29.
2006: Huizhen Liu; Kent Gunnertoft Jensen; Linh M Tran; Ming Chen; Lin Zhai; Carl Erik Olsen; Helmer Søhoel; Samuel R Denmeade; John T Isaacs; S Brøgger Christensen
Cytotoxic phenylpropanoids and an additional thapsigargin analogue isolated from Thapsia garganica.
Phytochemistry 2006;67(24):2651-8.
2006: John T Isaacs; Roberto Pili; Zheng (David) Qian; Susan L Dalrymple; Jason B Garrison; Natasha Kyprianou; Anders Björk; Anders Olsson; Tomas Leanderson
Identification of ABR-215050 as lead second generation quinoline-3-carboxamide anti-angiogenic agent for the treatment of prostate cancer.
The Prostate 2006;66(16):1768-78.
2006: Ivan V Litvinov; Vander Griend Donald; Lizamma Antony; Susan L Dalrymple; Angelo M DeMarzo; Charles G Drake; John T Isaacs
Androgen receptor as a licensing factor for DNA replication in androgen-sensitive prostate cancer cells.
Proceedings of the National Academy of Sciences of the United States of America 2006;103(41):15085-90.
2006: Saurabh Aggarwal; Pratap Singh; Ozlem Topaloglu; John T Isaacs; Samuel R Denmeade
A dimeric peptide that binds selectively to prostate-specific membrane antigen and inhibits its enzymatic activity.
Cancer research 2006;66(18):9171-7.
2006: P Singh; Aarti R Uzgare; Ivan V Litvinov; Samuel R Denmeade; John T Isaacs
Combinatorial androgen receptor targeted therapy for prostate cancer.
Endocrine-related cancer 2006;13(3):653-66.
2006: Ivan V Litvinov; Vander Griend Donald; Yi Xu; Lizamma Antony; Susan L Dalrymple; John T Isaacs
Low-calcium serum-free defined medium selects for growth of normal prostatic epithelial stem cells.
Cancer research 2006;66(17):8598-607.
2006: Ivan V Litvinov; Lizamma Antony; Susan L Dalrymple; Robyn Becker; Linzhao Cheng; John T Isaacs
PC3, but not DU145, human prostate cancer cells retain the coregulators required for tumor suppressor ability of androgen receptor.
The Prostate 2006;66(12):1329-38.
2006: Christopher J Strock; Jong-In Park; Eric K Nakakura; G Steven Bova; John T Isaacs; Douglas W Ball; Barry D Nelkin
Cyclin-dependent kinase 5 activity controls cell motility and metastatic potential of prostate cancer cells.
Cancer research 2006;66(15):7509-15.
2006: Yi Xu; Susan L Dalrymple; Robyn E Becker; Samuel R Denmeade; John T Isaacs
Pharmacologic basis for the enhanced efficacy of dutasteride against prostatic cancers.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(13):4072-9.
2006: Helmer Søhoel; Anne-Marie Lund Winther; Jesper V Møller; Poul Nissen; Samuel R Denmeade; John T Isaacs; Carl Erik Olsen; S Brøgger Christensen
Natural products as starting materials for development of second-generation SERCA inhibitors targeted towards prostate cancer cells.
Bioorganic & medicinal chemistry 2006;14(8):2810-5.
2006: Gurulingappa Hallur; Antonio Jimeno; Susan L Dalrymple; Tao Zhu; M Katherine Jung; Manuel Hidalgo; John T Isaacs; Saraswati Sukumar; Ernest Hamel; Saeed R Khan
Benzoylphenylurea sulfur analogues with potent antitumor activity.
Journal of medicinal chemistry 2006;49(7):2357-60.
2006: Samuel Janssen; D Marc Rosen; Rebecca M Ricklis; Craig Dionne; Hans Lilja; S Brøgger Christensen; John T Isaacs; Samuel R Denmeade
Pharmacokinetics, biodistribution, and antitumor efficacy of a human glandular kallikrein 2 (hK2)-activated thapsigargin prodrug.
The Prostate 2006;66(4):358-68.
2005: John T Isaacs
New strategies for the medical treatment of prostate cancer.
BJU international 2005;96 Suppl 2():35-40.
2005: Helmer Søhoel; Tommy Liljefors; Steven V Ley; Steven F Oliver; Alessandra Antonello; Martin D Smith; Carl Erik Olsen; John T Isaacs; S Brøgger Christensen
Total synthesis of two novel subpicomolar sarco/endoplasmatic reticulum Ca2+-ATPase inhibitors designed by an analysis of the binding site of thapsigargin.
Journal of medicinal chemistry 2005;48(22):7005-11.
2005: Susan L Dalrymple; Lizamma Antony; Yi Xu; Aarti R Uzgare; Julia Arnold; Jurga Savaugeot; Lori J Sokoll; Angelo M DeMarzo; John T Isaacs
Role of notch-1 and E-cadherin in the differential response to calcium in culturing normal versus malignant prostate cells.
Cancer research 2005;65(20):9269-79.
2005: Rolph Pfundt; Frank Smit; Corine Jansen; Tilly W Aalders; huub straatman; Walter A Van Der Vliet; John T Isaacs; Ad Geurts van Kessel; Jack A Schalken
Identification of androgen-responsive genes that are alternatively regulated in androgen-dependent and androgen-independent rat prostate tumors.
Genes, chromosomes & cancer 2005;43(3):273-83.
2005: Arthur L Burnett; Melissa F Kramer; Susan Dalrymple; John T Isaacs
Nonimmunosuppressant immunophilin ligand GPI-1046 does not promote in vitro growth of prostate cancer cells.
Urology 2005;65(5):1003-7.
2005: Pratap Singh; Annastasiah Mhaka; S Brøgger Christensen; Jeffrey J Gray; Samuel R Denmeade; John T Isaacs
Applying linear interaction energy method for rational design of noncompetitive allosteric inhibitors of the sarco- and endoplasmic reticulum calcium-ATPase.
Journal of medicinal chemistry 2005;48(8):3005-14.
2005: Aarti R Uzgare; John T Isaacs
Prostate cancer: potential targets of anti-proliferative and apoptotic signaling pathways.
The international journal of biochemistry & cell biology 2005;37(4):707-14.
2005: Pradip Roy-Burman; Donald J Tindall; Diane M Robins; Norman M Greenberg; Mary J C Hendrix; Suresh Mohla; Robert H Getzenberg; John T Isaacs; Kenneth Pienta
Androgens and prostate cancer: are the descriptors valid?
Cancer biology & therapy 2005;4(1):4-5.
2005: Samuel R Denmeade; John T Isaacs
The SERCA pump as a therapeutic target: making a "smart bomb" for prostate cancer.
Cancer biology & therapy 2005;4(1):14-22.
2004: Ivan V Litvinov; Lizamma Antony; John T Isaacs
Molecular characterization of an improved vector for evaluation of the tumor suppressor versus oncogene abilities of the androgen receptor.
The Prostate 2004;61(4):299-304.
2004: Sunil S Karhadkar; G Steven Bova; Nadia Abdallah; Surajit Dhara; Dale Gardner; Anirban Maitra; John T Isaacs; berman david; Philip A Beachy
Hedgehog signalling in prostate regeneration, neoplasia and metastasis.
Nature 2004;431(7009):707-12.
2004: Aarti R Uzgare; John T Isaacs
Enhanced redundancy in Akt and mitogen-activated protein kinase-induced survival of malignant versus normal prostate epithelial cells.
Cancer research 2004;64(17):6190-9.
2004: Georg Bartsch; J M Fitzpatrick; J A Schalken; John T Isaacs; J Nordling; C G Roehrborn
Consensus statement: the role of prostate-specific antigen in managing the patient with benign prostatic hyperplasia.
BJU international 2004;93 Suppl 1():27-9.
2004: Samuel R Denmeade; John T Isaacs
The role of prostate-specific antigen in the clinical evaluation of prostatic disease.
BJU international 2004;93 Suppl 1():10-5.
2004: Ivan V Litvinov; Chawnshang Chang; John T Isaacs
Molecular characterization of the commonly used human androgen receptor expression vector, pSG5-AR.
The Prostate 2004;58(4):319-24.
2004: Samuel R Denmeade; John T Isaacs
Development of prostate cancer treatment: the good news.
The Prostate 2004;58(3):211-24.
2004: John T Isaacs; William B Isaacs
Androgen receptor outwits prostate cancer drugs.
Nature medicine 2004;10(1):26-7.
2004: Aarti R Uzgare; Yi Xu; John T Isaacs
In vitro culturing and characteristics of transit amplifying epithelial cells from human prostate tissue.
Journal of cellular biochemistry 2004;91(1):196-205.
2003: Allen C Gao; Wei Lou; Jin-Tang Dong; J Carl Barrett; David Danielpour; John T Isaacs
Defining regulatory elements in the human KAI1 (CD 82) metastasis suppressor gene.
The Prostate 2003;57(4):256-60.
2003: Bruce Ruggeri; Jasbir Singh; Diane E Gingrich; Thelma S Angeles; Albom Mark; Shi Yang; Hong Chang; Candy Robinson; Kathryn Hunter; Pawel Dobrzanski; Susan Jones-Bolin; Sonya Pritchard; Lisa D Aimone; Andres Klein-Szanto; Jean-Marc Herbert; Francoise Bono; Paul Schaeffer; Pierre Casellas; Bernard Bourie; Roberto Pili; John T Isaacs; Mark A Ator; Robert L Hudkins; Jeffry L Vaught; John Mallamo; Craig Dionne
CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
Cancer research 2003;63(18):5978-91.
2003: Samuel R Denmeade; Carsten M Jakobsen; Samuel Janssen; Saeed R Khan; Elizabeth Garrett-Mayer; Hans Lilja; S Brøgger Christensen; John T Isaacs
Prostate-specific antigen-activated thapsigargin prodrug as targeted therapy for prostate cancer.
Journal of the National Cancer Institute 2003;95(13):990-1000.
2003: Ivan V Litvinov; Angelo M DeMarzo; John T Isaacs
Is the Achilles' heel for prostate cancer therapy a gain of function in androgen receptor signaling?
The Journal of clinical endocrinology and metabolism 2003;88(7):2972-82.
2003: Samuel R Denmeade; Ivan V Litvinov; Lori J Sokoll; Hans Lilja; John T Isaacs
Prostate-specific antigen (PSA) protein does not affect growth of prostate cancer cells in vitro or prostate cancer xenografts in vivo.
The Prostate 2003;56(1):45-53.
2003: Samuel R Denmeade; Lori J Sokoll; Susan L Dalrymple; D Marc Rosen; Alyssa M Gady; Debra J Bruzek; Rebecca M Ricklis; John T Isaacs
Dissociation between androgen responsiveness for malignant growth vs. expression of prostate specific differentiation markers PSA, hK2, and PSMA in human prostate cancer models.
The Prostate 2003;54(4):249-57.
2002: Annastasiah Mhaka; Samuel R Denmeade; Wei Yao; John T Isaacs; Saeed R Khan
A 5-fluorodeoxyuridine prodrug as targeted therapy for prostate cancer.
Bioorganic & medicinal chemistry letters 2002;12(17):2459-61.
2002: Samuel R Denmeade; John T Isaacs
A history of prostate cancer treatment.
Nature reviews. Cancer 2002;2(5):389-96.
2002: Bertrand Tombal; Samuel R Denmeade; J-M Gillis; John T Isaacs
A supramicromolar elevation of intracellular free calcium ([Ca(2+)](i)) is consistently required to induce the execution phase of apoptosis.
Cell death and differentiation 2002;9(5):561-73.
2002: Julia Arnold; John T Isaacs
Mechanisms involved in the progression of androgen-independent prostate cancers: it is not only the cancer cell's fault.
Endocrine-related cancer 2002;9(1):61-73.
2002: Jacek Pinski; Ashani T Weeraratna; Aarti R Uzgare; Julia Arnold; Samuel R Denmeade; John T Isaacs
Trk receptor inhibition induces apoptosis of proliferating but not quiescent human osteoblasts.
Cancer research 2002;62(4):986-9.
2001: Carsten M Jakobsen; Samuel R Denmeade; John T Isaacs; Alyssa M Gady; C E Olsen; S Brøgger Christensen
Design, synthesis, and pharmacological evaluation of thapsigargin analogues for targeting apoptosis to prostatic cancer cells.
Journal of medicinal chemistry 2001;44(26):4696-703.
2001: Jacek Pinski; A Parikh; G Steven Bova; John T Isaacs
Therapeutic implications of enhanced G(0)/G(1) checkpoint control induced by coculture of prostate cancer cells with osteoblasts.
Cancer research 2001;61(17):6372-6.
2001: Ashani T Weeraratna; Susan L Dalrymple; J C Lamb; Samuel R Denmeade; Sheila J Miknyoczki; Craig Dionne; John T Isaacs
Pan-trk inhibition decreases metastasis and enhances host survival in experimental models as a result of its selective induction of apoptosis of prostate cancer cells.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(8):2237-45.
2001: Ceshi Chen; W W Brabham; B G Stultz; Henry F Frierson; J C Barrett; C L Sawyers; John T Isaacs; Jin-Tang Dong
Defining a common region of deletion at 13q21 in human cancers.
Genes, chromosomes & cancer 2001;31(4):333-44.
2001: Samuel R Denmeade; Janita Lövgren; Saeed R Khan; Hans Lilja; John T Isaacs
Activation of latent protease function of pro-hK2, but not pro-PSA, involves autoprocessing.
The Prostate 2001;48(2):122-6.
2001: Kaspar Keledjian; Andrew Borkowski; G Kim; John T Isaacs; Stephen C Jacobs; Natasha Kyprianou
Reduction of human prostate tumor vascularity by the alpha1-adrenoceptor antagonist terazosin.
The Prostate 2001;48(2):71-8.
2001: J Gao; John T Isaacs
Mixed lineage kinase (MLK) family members are not involved in androgen regulation of prostatic proliferation or apoptosis.
The Prostate 2001;48(2):67-70.
2001: J Gao; Julia Arnold; John T Isaacs
Conversion from a paracrine to an autocrine mechanism of androgen-stimulated growth during malignant transformation of prostatic epithelial cells.
Cancer research 2001;61(13):5038-44.
2001: Samuel R Denmeade; Lori J Sokoll; Daniel W Chan; Saeed R Khan; John T Isaacs
Concentration of enzymatically active prostate-specific antigen (PSA) in the extracellular fluid of primary human prostate cancers and human prostate cancer xenograft models.
The Prostate 2001;48(1):1-6.
2001: Saeed R Khan; Annastasiah Mhaka; Roberto Pili; John T Isaacs
Modified synthesis and antiangiogenic activity of linomide.
Bioorganic & medicinal chemistry letters 2001;11(4):451-2.
2001: Takeshi Kurita; YZ Wang; Annemarie A Donjacour; C Zhao; J P Lydon; Bert W O'Malley; John T Isaacs; Rajvir Dahiya; Gerald R Cunha
Paracrine regulation of apoptosis by steroid hormones in the male and female reproductive system.
Cell death and differentiation 2001;8(2):192-200.
2000: Rena Lapidus; CAROL TIFFANY; John T Isaacs; Barbara Slusher
Prostate-specific membrane antigen (PSMA) enzyme activity is elevated in prostate cancer cells.
The Prostate 2000;45(4):350-4.
2000: Ashani T Weeraratna; Julia Arnold; D J George; Angelo M DeMarzo; John T Isaacs
Rational basis for Trk inhibition therapy for prostate cancer.
The Prostate 2000;45(2):140-8.
2000: John T Isaacs
Apoptosis: translating theory to therapy for prostate cancer.
Journal of the National Cancer Institute 2000;92(17):1367-9.
2000: Tomohiko Ichikawa; S Hosoki; Hiroshi Suzuki; Koichiro Akakura; Tatsuo Igarashi; Y Furuya; Mitsuo Oshimura; C W Rinker-Schaeffer; Naoki Nihei; J Carl Barrett; John T Isaacs; Haruo Ito
Mapping of metastasis suppressor genes for prostate cancer by microcell-mediated chromosome transfer.
Asian journal of andrology 2000;2(3):167-71.
2000: Jin-Tang Dong; Ceshi Chen; B G Stultz; John T Isaacs; Henry F Frierson
Deletion at 13q21 is associated with aggressive prostate cancers.
Cancer research 2000;60(14):3880-3.
2000: Bertrand Tombal; Ashani T Weeraratna; Samuel R Denmeade; John T Isaacs
Thapsigargin induces a calmodulin/calcineurin-dependent apoptotic cascade responsible for the death of prostatic cancer cells.
The Prostate 2000;43(4):303-17.
2000: Allen C Gao; Wei Lou; John T Isaacs
Enhanced GBX2 expression stimulates growth of human prostate cancer cells via transcriptional up-regulation of the interleukin 6 gene.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(2):493-7.
1999: Daniel E Epner; Akira Sawa; John T Isaacs
Glyceraldehyde-3-phosphate dehydrogenase expression during apoptosis and proliferation of rat ventral prostate.
Biology of reproduction 1999;61(3):687-91.
1999: S Brøgger Christensen; A Andersen; H Kromann; Marek Treiman; B Tombal; Samuel R Denmeade; John T Isaacs
Thapsigargin analogues for targeting programmed death of androgen-independent prostate cancer cells.
Bioorganic & medicinal chemistry 1999;7(7):1273-80.
1999: Samuel R Denmeade; X S Lin; Bertrand Tombal; John T Isaacs
Inhibition of caspase activity does not prevent the signaling phase of apoptosis in prostate cancer cells.
The Prostate 1999;39(4):269-79.
1999: JK Chon; Andrew Borkowski; Alan W Partin; John T Isaacs; Stephen C Jacobs; Natasha Kyprianou
Alpha 1-adrenoceptor antagonists terazosin and doxazosin induce prostate apoptosis without affecting cell proliferation in patients with benign prostatic hyperplasia.
The Journal of urology 1999;161(6):2002-8.
1999: D J George; Craig Dionne; Jitesh P Jani; Thelma S Angeles; Chikara Murakata; J Lamb; John T Isaacs
Sustained in vivo regression of Dunning H rat prostate cancers treated with combinations of androgen ablation and Trk tyrosine kinase inhibitors, CEP-751 (KT-6587) or CEP-701 (KT-5555).
Cancer research 1999;59(10):2395-401.
1999: Wei Lou; D Krill; Rajiv Dhir; Michael Becich; Jin-Tang Dong; H F Frierson; William B Isaacs; John T Isaacs; Allen C Gao
Methylation of the CD44 metastasis suppressor gene in human prostate cancer.
Cancer research 1999;59(10):2329-31.
1999: John T Isaacs
The biology of hormone refractory prostate cancer. Why does it develop?
The Urologic clinics of North America 1999;26(2):263-73.
1999: J Gao; Bertrand Tombal; John T Isaacs
Rapid in situ hybridization technique for detecting malignant mouse cell contamination in human xenograft tissue from nude mice and in vitro cultures from such xenografts.
The Prostate 1999;39(1):67-70.
1999: Bertrand Tombal; Samuel R Denmeade; John T Isaacs
Assessment and validation of a microinjection method for kinetic analysis of [Ca2+]i in individual cells undergoing apoptosis.
Cell calcium 1999;25(1):19-28.
1999: Allen C Gao; Wei Lou; T Ichikawa; Samuel R Denmeade; J Carl Barrett; John T Isaacs
Suppression of the tumorigenicity of prostatic cancer cells by gene(s) located on human chromosome 19p13.1-13.2.
The Prostate 1999;38(1):46-54.
1999: Naoki Nihei; S Ohta; Hiroaki Kuramochi; H Kugoh; Mitsuo Oshimura; J Carl Barrett; John T Isaacs; Tatsuo Igarashi; Haruo Ito; M Masai; Yayoi Ichikawa; Tomohiko Ichikawa
Metastasis suppressor gene(s) for rat prostate cancer on the long arm of human chromosome 7.
Genes, chromosomes & cancer 1999;24(1):1-8.
1998: H Suzuki; Jin-Tang Dong; Allen C Gao; J Carl Barrett; John T Isaacs
Identification of the rat homologue of KAI1 and its expression in Dunning rat prostate cancers.
The Prostate 1998;37(4):253-60.
1998: IB Joseph; John T Isaacs
Macrophage role in the anti-prostate cancer response to one class of antiangiogenic agents.
Journal of the National Cancer Institute 1998;90(21):1648-53.
1998: Craig Dionne; Anna Marie Camoratto; Jitesh P Jani; E Emerson; NT Neff; Jeffry L Vaught; Chikara Murakata; D Djakiew; J Lamb; G Steven Bova; D George; John T Isaacs
Cell cycle-independent death of prostate adenocarcinoma is induced by the trk tyrosine kinase inhibitor CEP-751 (KT6587).
Clinical cancer research : an official journal of the American Association for Cancer Research 1998;4(8):1887-98.
1998: J Gao; John T Isaacs
Development of an androgen receptor-null model for identifying the initiation site for androgen stimulation of proliferation and suppression of programmed (apoptotic) death of PC-82 human prostate cancer cells.
Cancer research 1998;58(15):3299-306.
1998: D J George; H Suzuki; G Steven Bova; John T Isaacs
Mutational analysis of the TrkA gene in prostate cancer.
The Prostate 1998;36(3):172-80.
1998: Samuel R Denmeade; A Nagy; J Gao; Hans Lilja; Andrew V Schally; John T Isaacs
Enzymatic activation of a doxorubicin-peptide prodrug by prostate-specific antigen.
Cancer research 1998;58(12):2537-40.
1998: Allen C Gao; Wei Lou; J P Sleeman; John T Isaacs
Metastasis suppression by the standard CD44 isoform does not require the binding of prostate cancer cells to hyaluronate.
Cancer research 1998;58(11):2350-2.
1998: Samuel R Denmeade; John T Isaacs
Enzymatic activation of prodrugs by prostate-specific antigen: targeted therapy for metastatic prostate cancer.
The cancer journal from Scientific American 1998;4 Suppl 1():S15-21.
1998: Allen C Gao; Wei Lou; John T Isaacs
Down-regulation of homeobox gene GBX2 expression inhibits human prostate cancer clonogenic ability and tumorigenicity.
Cancer research 1998;58(7):1391-4.
1997: IB Joseph; Joel B Nelson; Samuel R Denmeade; John T Isaacs
Androgens regulate vascular endothelial growth factor content in normal and malignant prostatic tissue.
Clinical cancer research : an official journal of the American Association for Cancer Research 1997;3(12 Pt 1):2507-11.
1997: X S Lin; Samuel R Denmeade; L Cisek; John T Isaacs
Mechanism and role of growth arrest in programmed (apoptotic) death of prostatic cancer cells induced by thapsigargin.
The Prostate 1997;33(3):201-7.
1997: Samuel R Denmeade; Wei Lou; Janita Lövgren; Johan Malm; Hans Lilja; John T Isaacs
Specific and efficient peptide substrates for assaying the proteolytic activity of prostate-specific antigen.
Cancer research 1997;57(21):4924-30.
1997: B Hartley-Asp; J Vukanovic; IB Joseph; K Strandgården; J Polacek; John T Isaacs
Anti-angiogenic treatment with linomide as adjuvant to surgical castration in experimental prostate cancer.
The Journal of urology 1997;158(3 Pt 1):902-7.
1997: Anna Marie Camoratto; Jitesh P Jani; Thelma S Angeles; Anna C Maroney; C Y Sanders; Chikara Murakata; NT Neff; Jeffry L Vaught; John T Isaacs; Craig Dionne
CEP-751 inhibits TRK receptor tyrosine kinase activity in vitro exhibits anti-tumor activity.
International journal of cancer. Journal international du cancer 1997;72(4):673-9.
1997: Yoko Kawana; Akira Komiya; Takeshi Ueda; Naoki Nihei; Hiroaki Kuramochi; Hiroshi Suzuki; R Yatani; T Imai; J T Dong; T Imai; O Yoshie; J Carl Barrett; John T Isaacs; Jun Shimazaki; Haruo Ito; Tomohiko Ichikawa
Location of KAI1 on the short arm of human chromosome 11 and frequency of allelic loss in advanced human prostate cancer.
The Prostate 1997;32(3):205-13.
1997: John T Isaacs
Molecular markers for prostate cancer metastasis. Developing diagnostic methods for predicting the aggressiveness of prostate cancer.
The American journal of pathology 1997;150(5):1511-21.
1997: Jin-Tang Dong; William B Isaacs; J Carl Barrett; John T Isaacs
Genomic organization of the human KAI1 metastasis-suppressor gene.
Genomics 1997;41(1):25-32.
1997: IB Joseph; John T Isaacs
Potentiation of the antiangiogenic ability of linomide by androgen ablation involves down-regulation of vascular endothelial growth factor in human androgen-responsive prostatic cancers.
Cancer research 1997;57(6):1054-7.
1997: Samuel R Denmeade; John T Isaacs
Prostate cancer: where are we and where are we going?
British journal of urology 1997;79 Suppl 1():2-7.
1997: Allen C Gao; Wei Lou; Jin-Tang Dong; John T Isaacs
CD44 is a metastasis suppressor gene for prostatic cancer located on human chromosome 11p13.
Cancer research 1997;57(5):846-9.
1997: Samuel R Denmeade; Diane E McCloskey; IB Joseph; Hillary A Hahm; John T Isaacs; Nancy E Davidson
Apoptosis in hormone-responsive malignancies.
Advances in pharmacology (San Diego, Calif.) 1997;41():553-83.
1997: Jin-Tang Dong; William B Isaacs; John T Isaacs
Molecular advances in prostate cancer.
Current opinion in oncology 1997;9(1):101-7.
1996: Allen C Gao; John T Isaacs
Expression of homeobox gene-GBX2 in human prostatic cancer cells.
The Prostate 1996;29(6):395-8.
1996: Jin-Tang Dong; H Suzuki; Sokhom Pin; G Steven Bova; J A Schalken; William B Isaacs; J Carl Barrett; John T Isaacs
Down-regulation of the KAI1 metastasis suppressor gene during the progression of human prostatic cancer infrequently involves gene mutation or allelic loss.
Cancer research 1996;56(19):4387-90.
1996: IB Joseph; John T Isaacs
The antiangiogenic agent linomide inhibits tumor necrosis factor-alpha secretion via inhibition of its synthesis.
The Prostate 1996;29(3):183-90.
1996: IB Joseph; J Vukanovic; John T Isaacs
Antiangiogenic treatment with linomide as chemoprevention for prostate, seminal vesicle, and breast carcinogenesis in rodents.
Cancer research 1996;56(15):3404-8.
1996: John T Isaacs
The R-3327 system of rat prostatic cancers.
Urologic oncology 1996;2(4):115-6.
1996: Carrie W Rinker-Schaeffer; J F Wharam; J Simons; John T Isaacs
Development of a high-efficiency method for gene marking of Dunning prostate cancer cell lines with the enzyme beta-galactosidase.
The Prostate 1996;29(1):60-4.
1996: Samuel R Denmeade; X S Lin; John T Isaacs
Role of programmed (apoptotic) cell death during the progression and therapy for prostate cancer.
The Prostate 1996;28(4):251-65.
1996: Y Furuya; S Krajewski; Jonathan I Epstein; J C Reed; John T Isaacs
Expression of bcl-2 and the progression of human and rodent prostatic cancers.
Clinical cancer research : an official journal of the American Association for Cancer Research 1996;2(2):389-98.
1996: Samuel R Denmeade; John T Isaacs
Activation of programmed (apoptotic) cell death for the treatment of prostate cancer.
Advances in pharmacology (San Diego, Calif.) 1996;35():281-306.
1996: Jin-Tang Dong; Carrie W Rinker-Schaeffer; T Ichikawa; J Carl Barrett; John T Isaacs
Prostate cancer--biology of metastasis and its clinical implications.
World journal of urology 1996;14(3):182-9.
1996: Tomohiko Ichikawa; Naoki Nihei; Hiroaki Kuramochi; Y Kawana; A M Killary; J Carl Barrett; John T Isaacs; H Kugoh; M Oshimura; Jun Shimazaki
Metastasis suppressor genes for prostate cancer.
The Prostate. Supplement 1996;6():31-5.
1995: Yuzo Furuya; John T Isaacs; Jun Shimazaki
Induction of programmed death/apoptosis androgen-dependent mouse mammary tumor cell line (Shionogi Carcinoma 115) by androgen withdrawal.
Japanese journal of cancer research : Gann 1995;86(12):1159-65.
1995: Carrie W Rinker-Schaeffer; Anita L Hawkins; S L Su; R S Israeli; Constance A Griffin; John T Isaacs; Warren D W Heston
Localization and physical mapping of the prostate-specific membrane antigen (PSM) gene to human chromosome 11.
Genomics 1995;30(1):105-8.
1995: Naoki Nihei; Tomohiko Ichikawa; Y Kawana; Hiroaki Kuramochi; H Kugo; M Oshimura; A M Killary; C W Rinker-Schaeffer; J Carl Barrett; John T Isaacs
Localization of metastasis suppressor gene(s) for rat prostatic cancer to the long arm of human chromosome 10.
Genes, chromosomes & cancer 1995;14(2):112-9.
1995: J Vukanovic; John T Isaacs
Human prostatic cancer cells are sensitive to programmed (apoptotic) death induced by the antiangiogenic agent linomide.
Cancer research 1995;55(16):3517-20.
1995: Jin-Tang Dong; Patricia W Lamb; Carrie W Rinker-Schaeffer; J Vukanovic; T Ichikawa; John T Isaacs; J Carl Barrett
KAI1, a metastasis suppressor gene for prostate cancer on human chromosome 11p11.2.
Science (New York, N.Y.) 1995;268(5212):884-6.
1995: R R Berges; J Vukanovic; Jonathan I Epstein; M CarMichel; L Cisek; D E Johnson; Robert W Veltri; Patrick C Walsh; John T Isaacs
Implication of cell kinetic changes during the progression of human prostatic cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 1995;1(5):473-80.
1995: Y Furuya; X S Lin; J C Walsh; William G Nelson; John T Isaacs
Androgen ablation-induced programmed death of prostatic glandular cells does not involve recruitment into a defective cell cycle or p53 induction.
Endocrinology 1995;136(5):1898-906.
1995: J Vukanovic; Beryl Hartley-Asp; John T Isaacs
Inhibition of tumor angiogenesis and the therapeutic ability of linomide against rat prostatic cancers.
The Prostate 1995;26(5):235-46.
1995: J Vukanovic; John T Isaacs
Linomide inhibits angiogenesis, growth, metastasis, and macrophage infiltration within rat prostatic cancers.
Cancer research 1995;55(7):1499-504.
1995: X Lin; Samuel R Denmeade; John T Isaacs
The genetics of programmed (apoptotic) cell death.
Cancer surveys 1995;25():173-94.
1994: Y Furuya; John T Isaacs
Proliferation-dependent vs. independent programmed cell death of prostatic cancer cells involves distinct gene regulation.
The Prostate 1994;25(6):301-9.
1994: Carrie W Rinker-Schaeffer; Anita L Hawkins; N Ru; J Dong; G Stoica; Constance A Griffin; T Ichikawa; J Carl Barrett; John T Isaacs
Differential suppression of mammary and prostate cancer metastasis by human chromosomes 17 and 11.
Cancer research 1994;54(23):6249-56.
1994: Y Furuya; P Lundmo; A D Short; Donald L Gill; John T Isaacs
The role of calcium, pH, and cell proliferation in the programmed (apoptotic) death of androgen-independent prostatic cancer cells induced by thapsigargin.
Cancer research 1994;54(23):6167-75.
1994: Carrie W Rinker-Schaeffer; Alan W Partin; William B Isaacs; Donald S Coffey; John T Isaacs
Molecular and cellular changes associated with the acquisition of metastatic ability by prostatic cancer cells.
The Prostate 1994;25(5):249-65.
1994: Deborah K Armstrong; Scott H Kaufmann; YVONNE OTTAVIANO; Y Furuya; J A Buckley; John T Isaacs; Nancy E Davidson
Epidermal growth factor-mediated apoptosis of MDA-MB-468 human breast cancer cells.
Cancer research 1994;54(20):5280-3.
1994: John T Isaacs; Y Furuya; R Berges
The role of androgen in the regulation of programmed cell death/apoptosis in normal and malignant prostatic tissue.
Seminars in cancer biology 1994;5(5):391-400.
1994: Tomohiko Ichikawa; Naoki Nihei; H Suzuki; M Oshimura; M Emi; Y Nakamura; I Hayata; John T Isaacs; Jun Shimazaki
Suppression of metastasis of rat prostatic cancer by introducing human chromosome 8.
Cancer research 1994;54(9):2299-302.
1994: John T Isaacs
Advances and controversies in the study of programmed cell death/apoptosis in the development of and therapy for cancer.
Current opinion in oncology 1994;6(1):82-9.
1994: John T Isaacs
Role of androgens in prostatic cancer.
Vitamins and hormones 1994;49():433-502.
1994: John T Isaacs
Etiology of benign prostatic hyperplasia.
European urology 1994;25 Suppl 1():6-9.
1993: Y Furuya; John T Isaacs
Differential gene regulation during programmed death (apoptosis) versus proliferation of prostatic glandular cells induced by androgen manipulation.
Endocrinology 1993;133(6):2660-6.
1993: John T Isaacs
Role of programmed cell death in carcinogenesis.
Environmental health perspectives 1993;101 Suppl 5():27-33.
1993: R R Berges; Y Furuya; L Remington; H F English; Tyler Jacks; John T Isaacs
Cell proliferation, DNA repair, and p53 function are not required for programmed death of prostatic glandular cells induced by androgen ablation.
Proceedings of the National Academy of Sciences of the United States of America 1993;90(19):8910-4.
1993: D E Epner; Alan W Partin; J A Schalken; John T Isaacs; Donald S Coffey
Association of glyceraldehyde-3-phosphate dehydrogenase expression with cell motility and metastatic potential of rat prostatic adenocarcinoma.
Cancer research 1993;53(9):1995-7.
1993: J Vukanovic; Antonino Passaniti; T Hirata; R J Traystman; Beryl Hartley-Asp; John T Isaacs
Antiangiogenic effects of the quinoline-3-carboxamide linomide.
Cancer research 1993;53(8):1833-7.
1993: Carrie W Rinker-Schaeffer; William B Isaacs; John T Isaacs
Molecular and cellular markers for metastatic prostate cancer.
Cancer metastasis reviews 1993;12(1):3-10.
1993: John T Isaacs
Prostatic cancer: an overview.
Cancer metastasis reviews 1993;12(1):1-2.
1993: Beth Levine; Q Huang; John T Isaacs; J C Reed; Diane E Griffin; J Marie Hardwick
Conversion of lytic to persistent alphavirus infection by the bcl-2 cellular oncogene.
Nature 1993;361(6414):739-42.
1993: R Berges; John T Isaacs
Programming events in the regulation of cell proliferation and death.
Clinical chemistry 1993;39(2):356-61.
1993: John T Isaacs
Prostatic cancer: an age-old problem.
Advances in experimental medicine and biology 1993;330():167-84.
1993: R J van Moorselaar; T Ichikawa; H E Schaafsma; P H Jap; John T Isaacs; P van Stratum; Frans C S Ramaekers; F M Debruyne; Jack A Schalken
The rat bladder tumor model system RBT resembles phenotypically and cytogenetically human superficial transitional cell carcinoma.
Urological research 1993;21(6):413-21.
1992: John T Isaacs; P I Lundmo; R Berges; P Martikainen; Natasha Kyprianou; H F English
Androgen regulation of programmed death of normal and malignant prostatic cells.
Journal of andrology 1992;13(6):457-64.
1992: T Ichikawa; Y Ichikawa; J Dong; Anita L Hawkins; Constance A Griffin; William B Isaacs; Mitsuo Oshimura; J Carl Barrett; John T Isaacs
Localization of metastasis suppressor gene(s) for prostatic cancer to the short arm of human chromosome 11.
Cancer research 1992;52(12):3486-90.
1992: Deborah K Armstrong; John T Isaacs; YVONNE OTTAVIANO; Nancy E Davidson
Programmed cell death in an estrogen-independent human breast cancer cell line, MDA-MB-468.
Cancer research 1992;52(12):3418-24.
1992: T Ichikawa; J C Lamb; P I Christensson; Beryl Hartley-Asp; John T Isaacs
The antitumor effects of the quinoline-3-carboxamide linomide on Dunning R-3327 rat prostatic cancers.
Cancer research 1992;52(11):3022-8.
1992: M J G Bussemakers; R J van Moorselaar; LA Giroldi; T Ichikawa; John T Isaacs; M Takeichi; F M Debruyne; Jack A Schalken
Decreased expression of E-cadherin in the progression of rat prostatic cancer.
Cancer research 1992;52(10):2916-22.
1992: Antonino Passaniti; John T Isaacs; J A Haney; S W Adler; T J Cujdik; P V Long; H K Kleinman
Stimulation of human prostatic carcinoma tumor growth in athymic mice and control of migration in culture by extracellular matrix.
International journal of cancer. Journal international du cancer 1992;51(2):318-24.
1992: T W Redding; Andrew V Schally; Sinisa Radulovic; S Milovanovic; Karoly Szepeshazi; John T Isaacs
Sustained release formulations of luteinizing hormone-releasing hormone antagonist SB-75 inhibit proliferation and enhance apoptotic cell death of human prostate carcinoma (PC-82) in male nude mice.
Cancer research 1992;52(9):2538-44.
1992: T Ichikawa; Y Ichikawa; John T Isaacs
Genetic factors and suppression of metastatic ability of v-Ha-ras-transfected rat mammary cancer cells.
Proceedings of the National Academy of Sciences of the United States of America 1992;89(5):1607-10.
1992: J C Lamb; H English; P L Levandoski; G R Rhodes; R K Johnson; John T Isaacs
Prostatic involution in rats induced by a novel 5 alpha-reductase inhibitor, SK&F 105657: role for testosterone in the androgenic response.
Endocrinology 1992;130(2):685-94.
1992: J C Lamb; M A Levy; R K Johnson; John T Isaacs
Response of rat and human prostatic cancers to the novel 5 alpha-reductase inhibitor, SK&F 105657.
The Prostate 1992;21(1):15-34.
1992: John T Isaacs; William B Isaacs; J Schalken
Comparative aspects of multistep prostatic carcinogenesis in humans and rodents.
Progress in clinical and biological research 1992;376():261-88.
1992: Kenneth Pienta; B C Murphy; William B Isaacs; John T Isaacs; Donald S Coffey
Effect of pentosan, a novel cancer chemotherapeutic agent, on prostate cancer cell growth and motility.
The Prostate 1992;20(3):233-41.
1992: John T Isaacs
Hormonal balance and the risk of prostatic cancer.
Journal of cellular biochemistry. Supplement 1992;16H():107-8.
1991: P Martikainen; Natasha Kyprianou; R W Tucker; John T Isaacs
Programmed death of nonproliferating androgen-independent prostatic cancer cells.
Cancer research 1991;51(17):4693-700.
1991: T Ichikawa; Y Ichikawa; John T Isaacs
Genetic factors and suppression of metastatic ability of prostatic cancer.
Cancer research 1991;51(14):3788-92.
1991: A Tjota; MARIA LEE; John T Isaacs; N Kadohama; C L Lee
Murine monoclonal antibodies reactive with a variety of androgen independent Dunning rat prostate adenocarcinoma sublines also reactive with human prostate adenocarcinoma.
The Journal of urology 1991;146(1):205-12.
1991: John T Isaacs
A mammary cancer suppressor gene and its site of action in the rat.
Cancer research 1991;51(6):1591-5.
1991: Natasha Kyprianou; Richard B Alexander; John T Isaacs
Activation of programmed cell death by recombinant human tumor necrosis factor plus topoisomerase II-targeted drugs in L929 tumor cells.
Journal of the National Cancer Institute 1991;83(5):346-50.
1991: Gary D Steinberg; Charles B Brendler; Robert A. Squire; John T Isaacs
Experimental intravesical therapy for superficial transitional cell carcinoma in a rat bladder tumor model.
The Journal of urology 1991;145(3):647-53.
1991: P Björk; John T Isaacs; Beryl Hartley-Asp
Estramustine binding protein (EMBP) in rat R3327 Dunning tumors: partial characterization and effect of hormonal withdrawal, hormonal replacement, and cytotoxic treatment on its expression.
The Prostate 1991;18(3):181-200.
1991: T Ichikawa; J A Schalken; Y Ichikawa; Gary D Steinberg; John T Isaacs
H-ras expression, genetic instability, and acquisition of metastatic ability by rat prostatic cancer cells following v-H-ras oncogene transfection.
The Prostate 1991;18(2):163-72.
1991: P E Juniewicz; N Fetrow; J Marinelli; M Wolf; E Young; J Lamb; John T Isaacs
Evaluation of Win 49,596, a novel steroidal androgen receptor antagonist, in animal models of prostate cancer.
The Prostate 1991;18(2):105-15.
1991: Natasha Kyprianou; H F English; Nancy E Davidson; John T Isaacs
Programmed cell death during regression of the MCF-7 human breast cancer following estrogen ablation.
Cancer research 1991;51(1):162-6.
1991: T Ichikawa; Y Ichikawa; John T Isaacs
Genetic factors and metastatic potential of prostatic cancer.
Cancer surveys 1991;11():35-42.
1991: Natasha Kyprianou; P Martikainen; L Davis; H F English; John T Isaacs
Programmed cell death as a new target for prostatic cancer therapy.
Cancer surveys 1991;11():265-77.
1991: John T Isaacs
Introduction: survey of outstanding problems in the management of prostatic cancer.
Cancer surveys 1991;11():1-3.
1990: P Martikainen; Natasha Kyprianou; John T Isaacs
Effect of transforming growth factor-beta 1 on proliferation and death of rat prostatic cells.
Endocrinology 1990;127(6):2963-8.
1990: Gary D Steinberg; Charles B Brendler; T Ichikawa; Robert A. Squire; John T Isaacs
Characterization of an N-methyl-N-nitrosourea-induced autochthonous rat bladder cancer model.
Cancer research 1990;50(20):6668-74.
1990: T Ichikawa; Natasha Kyprianou; John T Isaacs
Genetic instability and the acquisition of metastatic ability by rat mammary cancer cells following v-H-ras oncogene transfection.
Cancer research 1990;50(19):6349-57.
1990: P Martikainen; John T Isaacs
An organ culture system for the study of programmed cell death in the rat ventral prostate.
Endocrinology 1990;127(3):1268-77.
1990: Natasha Kyprianou; H F English; John T Isaacs
Programmed cell death during regression of PC-82 human prostate cancer following androgen ablation.
Cancer research 1990;50(12):3748-53.
1990: H Ballentine Carter; Steven Piantadosi; John T Isaacs
Clinical evidence for and implications of the multistep development of prostate cancer.
The Journal of urology 1990;143(4):742-6.
1990: Natasha Kyprianou; John T Isaacs
Relationship between metastatic ability and H-ras oncogene expression in rat mammary cancer cells transfected with the v-H-ras oncogene.
Cancer research 1990;50(5):1449-54.
1990: Y Matuo; Nozomu Nishi; H Takasuka; Y Masuda; K Nishikawa; John T Isaacs; P S Adams; W L McKeehan; G H Sato
Production and significance of TGF-beta in AT-3 metastatic cell line established from the Dunning rat prostatic adenocarcinoma.
Biochemical and biophysical research communications 1990;166(2):840-7.
1990: Ronald A Morton; John T Isaacs; William B Isaacs
Differential effects of growth factor antagonists on neoplastic and normal prostatic cells.
The Prostate 1990;17(4):327-36.
1990: H Schulze; John T Isaacs
Development of hormone refractory tumors: adaption versus clonal selection.
Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer 1990;118():153-62.
1990: P Martikainen; John T Isaacs
Role of calcium in the programmed death of rat prostatic glandular cells.
The Prostate 1990;17(3):175-87.
1990: William B Isaacs; John T Isaacs; Natasha Kyprianou; J K Burgers; Richard B Alexander; Alan W Partin; J L Mohler; Fray F Marshall; Donald S Coffey
New approaches to the evaluation of the metastatic ability of renal cancer and new approaches to chemotherapy.
European urology 1990;18 Suppl 2():33-5.
1990: H Ballentine Carter; John T Isaacs
Overview of hormonal therapy for prostate cancer.
Progress in clinical and biological research 1990;350():129-40.
1990: K R Newhall; John T Isaacs; George L Wright
Dunning rat prostate tumors and cultured cell lines fail to express human prostate carcinoma-associated antigens.
The Prostate 1990;17(4):317-25.
1990: B S Carter; H Ballentine Carter; John T Isaacs
Epidemiologic evidence regarding predisposing factors to prostate cancer.
The Prostate 1990;16(3):187-97.
1990: John T Isaacs
Importance of the natural history of benign prostatic hyperplasia in the evaluation of pharmacologic intervention.
The Prostate. Supplement 1990;3():1-7.
1989: Natasha Kyprianou; John T Isaacs
"Thymineless" death in androgen-independent prostatic cancer cells.
Biochemical and biophysical research communications 1989;165(1):73-81.
1989: John T Isaacs
Relationship between tumor size and curability of prostatic cancer by combined chemo-hormonal therapy in rats.
Cancer research 1989;49(22):6290-4.
1989: Natasha Kyprianou; John T Isaacs
Expression of transforming growth factor-beta in the rat ventral prostate during castration-induced programmed cell death.
Molecular endocrinology (Baltimore, Md.) 1989;3(10):1515-22.
1989: J M Henry; John T Isaacs
Synergistic enhancement of the efficacy of the bioreductively activated alkylating agent RSU-1164 in the treatment of prostatic cancer by photodynamic therapy.
The Journal of urology 1989;142(1):165-70.
1989: J K Burgers; Fray F Marshall; John T Isaacs
Enhanced anti-tumor effects of recombinant human tumor necrosis factor plus VP-16 on metastatic renal cell carcinoma in a xenograft model.
The Journal of urology 1989;142(1):160-4.
1989: Frans C S Ramaekers; A P Verhagen; John T Isaacs; W F J Feitz; O Moesker; G Schaart; Jack A Schalken; G Peter Vooijs
Intermediate filament expression and the progression of prostatic cancer as studied in the Dunning R-3327 rat prostatic carcinoma system.
The Prostate 1989;14(4):323-39.
1989: John T Isaacs; Natasha Kyprianou
Biological basis for chemohormonal therapy for prostatic cancer.
Cancer treatment and research 1989;46():177-93.
1989: H F English; Natasha Kyprianou; John T Isaacs
Relationship between DNA fragmentation and apoptosis in the programmed cell death in the rat prostate following castration.
The Prostate 1989;15(3):233-50.
1989: John T Isaacs; Donald S Coffey
Etiology and disease process of benign prostatic hyperplasia.
The Prostate. Supplement 1989;2():33-50.
1989: Jonathan P Jarow; John T Isaacs
Prostatic growth effects of rat urogenital sinus and human prostatic tissue in the rat.
The Prostate 1989;14(4):301-8.
1988: B Treiger; John T Isaacs
Expression of a transfected v-Harvey-ras oncogene in a Dunning rat prostate adenocarcinoma and the development of high metastatic ability.
The Journal of urology 1988;140(6):1580-6.
1988: H Ballentine Carter; John T Isaacs
Experimental and theoretical basis for hormonal treatment of prostatic cancer.
Seminars in urology 1988;6(4):262-8.
1988: Alan W Partin; John T Isaacs; B Treiger; Donald S Coffey
Early cell motility changes associated with an increase in metastatic ability in rat prostatic cancer cells transfected with the v-Harvey-ras oncogene.
Cancer research 1988;48(21):6050-3.
1988: Y Matuo; Nozomu Nishi; H Tanaka; I Sasaki; John T Isaacs; F Wada
Production of IGF-II-related peptide by an anaplastic cell line (AT-3) established from the Dunning prostatic carcinoma of rats.
In vitro cellular & developmental biology : journal of the Tissue Culture Association 1988;24(10):1053-6.
1988: Natasha Kyprianou; John T Isaacs
Identification of a cellular receptor for transforming growth factor-beta in rat ventral prostate and its negative regulation by androgens.
Endocrinology 1988;123(4):2124-31.
1988: James L Mohler; Alan W Partin; John T Isaacs; Donald S Coffey
Metastatic potential prediction by a visual grading system of cell motility: prospective validation in the Dunning R-3327 prostatic adenocarcinoma model.
Cancer research 1988;48(15):4312-7.
1988: J M Henry; John T Isaacs
Relationship between tumor size and the curability of metastatic prostatic cancer by surgery alone or in combination with adjuvant chemotherapy.
The Journal of urology 1988;139(5):1119-23.
1988: J A Schalken; S B Ebeling; John T Isaacs; B Treiger; M J Bussemakers; M E de Jong; W J Van de Ven
Down modulation of fibronectin messenger RNA in metastasizing rat prostatic cancer cells revealed by differential hybridization analysis.
Cancer research 1988;48(8):2042-6.
1988: John T Isaacs
Inheritance of a genetic factor from the Copenhagen rat and the suppression of chemically induced mammary adenocarcinogenesis.
Cancer research 1988;48(8):2204-13.
1988: H Schulze; John T Isaacs; Theodor Senge
[Recent findings on the pathogenesis and therapy of prostatic cancer].
Der Urologe. Ausg. A 1988;27(2):105-10.
1988: Natasha Kyprianou; John T Isaacs
Activation of programmed cell death in the rat ventral prostate after castration.
Endocrinology 1988;122(2):552-62.
1988: D B Cooke; V E Quarmby; D D Mickey; John T Isaacs; Frank S French
Oncogene expression in prostate cancer: Dunning R3327 rat dorsal prostatic adenocarcinoma system.
The Prostate 1988;13(4):263-72.
1988: John T Isaacs; B Hukku
Nonrandom involvement of chromosome 4 in the progression of rat prostatic cancer.
The Prostate 1988;13(2):165-88.
1988: D B Cooke; V E Quarmby; Peter Petrusz; D D Mickey; Channing J Der; John T Isaacs; Frank S French
Expression of ras proto-oncogenes in the Dunning R3327 rat prostatic adenocarcinoma system.
The Prostate 1988;13(4):273-87.
1988: Natasha Kyprianou; H F English; John T Isaacs
Activation of a Ca2+-Mg2+-dependent endonuclease as an early event in castration-induced prostatic cell death.
The Prostate 1988;13(2):103-17.
1987: Richard B Alexander; John T Isaacs; Donald S Coffey
Tumor necrosis factor enhances the in vitro and in vivo efficacy of chemotherapeutic drugs targeted at DNA topoisomerase II in the treatment of murine bladder cancer.
The Journal of urology 1987;138(2):427-9.
1987: H Schulze; John T Isaacs; T Senge
Inability of complete androgen blockade to increase survival of patients with advanced prostatic cancer as compared to standard hormonal therapy.
The Journal of urology 1987;137(5):909-11.
1987: Y Matuo; N Nishi; S Matsui; A A Sandberg; John T Isaacs; F Wada
Heparin binding affinity of rat prostatic growth factor in normal and cancerous prostates: partial purification and characterization of rat prostatic growth factor in the Dunning tumor.
Cancer research 1987;47(1):188-92.
1987: H F English; Richard J Santen; John T Isaacs
Response of glandular versus basal rat ventral prostatic epithelial cells to androgen withdrawal and replacement.
The Prostate 1987;11(3):229-42.
1987: Natasha Kyprianou; John T Isaacs
Quantal relationship between prostatic dihydrotestosterone and prostatic cell content: critical threshold concept.
The Prostate 1987;11(1):41-50.
1987: Natasha Kyprianou; John T Isaacs
Biological significance of measurable androgen levels in the rat ventral prostate following castration.
The Prostate 1987;10(4):313-24.
1987: N Nishi; Y Matuo; S Matsui; A A Sandberg; John T Isaacs; F Wada
Isolation of a 41 kilodalton cytosol protein from the Dunning rat prostatic adenocarcinoma: characterization as depolymerized actin isomers.
The Prostate 1987;10(4):303-12.
1987: John T Isaacs; H Schulze; Donald S Coffey
Development of androgen resistance in prostatic cancer.
Progress in clinical and biological research 1987;243A():21-31.
1987: H Schulze; John T Isaacs; Donald S Coffey
A critical review of the concept of total androgen ablation in the treatment of prostate cancer.
Progress in clinical and biological research 1987;243A():1-19.
1987: John T Isaacs
Development and characteristics of the available animal model systems for the study of prostatic cancer.
Progress in clinical and biological research 1987;239():513-76.
1987: John T Isaacs; Natasha Kyprianou
Development of androgen-independent tumor cells and their implication for the treatment of prostatic cancer.
Urological research 1987;15(3):133-8.
1986: John T Isaacs
Genetic control of resistance to chemically induced mammary adenocarcinogenesis in the rat.
Cancer research 1986;46(8):3958-63.
1986: Jonathan P Jarow; F F Marshall; John T Isaacs
A chicken chorioallantoic membrane assay for the evaluation of the androgen responsiveness of prostatic tissue.
The Journal of urology 1986;135(6):1312-8.
1986: John T Isaacs; William B Isaacs; W F Feitz; J Scheres
Establishment and characterization of seven Dunning rat prostatic cancer cell lines and their use in developing methods for predicting metastatic abilities of prostatic cancers.
The Prostate 1986;9(3):261-81.
1986: H Schulze; John T Isaacs
Biology and therapy of prostatic cancer.
Cancer surveys 1986;5(3):487-503.
1985: W J Ellis; John T Isaacs
Effectiveness of complete versus partial androgen withdrawal therapy for the treatment of prostatic cancer as studied in the Dunning R-3327 system of rat prostatic adenocarcinomas.
Cancer research 1985;45(12 Pt 1):6041-50.
1985: John T Isaacs
Determination of the number of events required for mammary carcinogenesis in the Sprague-Dawley female rat.
Cancer research 1985;45(10):4827-32.
1985: C B Brendler; A L Follansbee; John T Isaacs
Discrimination between normal, hyperplastic and malignant human prostatic tissues by enzymatic profiles.
The Journal of urology 1985;133(3):495-501.
1985: John T Isaacs
New principles in the management of metastatic prostatic cancer.
Progress in clinical and biological research 1985;185A():383-405.
1984: John T Isaacs
The aging ACI/Seg versus Copenhagen male rat as a model system for the study of prostatic carcinogenesis.
Cancer research 1984;44(12 Pt 1):5785-96.
1984: C B Brendler; John T Isaacs; A L Follansbee; Patrick C Walsh
The use of multiple variables to predict response to endocrine therapy in carcinoma of the prostate: a preliminary report.
The Journal of urology 1984;131(4):694-700.
1984: S J Berry; John T Isaacs
Comparative aspects of prostatic growth and androgen metabolism with aging in the dog versus the rat.
Endocrinology 1984;114(2):511-20.
1984: F C Lowe; John T Isaacs
Biochemical methods for predicting metastatic ability of prostatic cancer utilizing the dunning R-3327 rat prostatic adenocarcinoma system as a model.
Cancer research 1984;44(2):744-52.
1984: John T Isaacs
The timing of androgen ablation therapy and/or chemotherapy in the treatment of prostatic cancer.
The Prostate 1984;5(1):1-17.
1984: John T Isaacs
Antagonistic effect of androgen on prostatic cell death.
The Prostate 1984;5(5):545-57.
1984: John T Isaacs
Common characteristics of human and canine benign prostatic hyperplasia.
Progress in clinical and biological research 1984;145():217-34.
1983: John T Isaacs
Changes in dihydrotestosterone metabolism and the development of benign prostatic hyperplasia in the aging beagle.
Journal of steroid biochemistry 1983;18(6):749-57.
1983: John T Isaacs
Prostatic structure and function in relation to the etiology of prostatic cancer.
The Prostate 1983;4(4):351-66.
1983: John T Isaacs; C B Brendler; Patrick C Walsh
Changes in the metabolism of dihydrotestosterone in the hyperplastic human prostate.
The Journal of clinical endocrinology and metabolism 1983;56(1):139-46.
1982: John T Isaacs
Hormonally responsive versus unresponsive progression of prostatic cancer to antiandrogen therapy as studied with the Dunning R-3327-AT and -G rat adenocarcinomas.
Cancer research 1982;42(12):5010-4.
1982: N Wake; John T Isaacs; A A Sandberg
Chromosomal changes associated with progression of the Dunning R-3327 rat prostatic adenocarcinoma system.
Cancer research 1982;42(10):4131-42.
1982: J E Humphries; John T Isaacs
Unusual androgen sensitivity of the androgen-independent Dunning R-3327-G rat prostatic adenocarcinoma: androgen effect on tumor cell loss.
Cancer research 1982;42(8):3148-56.
1982: John T Isaacs; N Wake; Donald S Coffey; A A Sandberg
Genetic instability coupled to clonal selection as a mechanism for tumor progression in the Dunning R-3327 rat prostatic adenocarcinoma system.
Cancer research 1982;42(6):2353-71.
1982: M S Gesell; M J Brandes; E A Arnold; John T Isaacs; H Ueda; J C Millan; D Brandes
Retinoic acid binding protein in normal and neopolastic rat prostate.
The Prostate 1982;3(2):131-8.
1982: J S Elder; John T Isaacs; Patrick C Walsh
Androgenic sensitivity of the gubernaculum testis: evidence for hormonal/mechanical interactions in testicular descent.
The Journal of urology 1982;127(1):170-6.
1981: John T Isaacs; Donald S Coffey
Adaptation versus selection as the mechanism responsible for the relapse of prostatic cancer to androgen ablation therapy as studied in the Dunning R-3327-H adenocarcinoma.
Cancer research 1981;41(12 Pt 1):5070-5.
1981: John T Isaacs; G W Yu; Donald S Coffey
The characterization of a newly identified, highly metastatic variety of Dunning R 3327 rat prostatic adenocarcinoma system: the MAT LyLu tumor.
Investigative urology 1981;19(1):20-3.
1981: R J Ehrlichman; John T Isaacs; Donald S Coffey
Differences in the effects of estradiol on dihydrotestosterone induced prostatic growth of the castrate dog and rat.
Investigative urology 1981;18(8):466-70.
1981: Donald S Coffey; John T Isaacs
Prostate tumor biology and cell kinetics--theory.
Urology 1981;17(Suppl 3):40-53.
1981: Donald S Coffey; John T Isaacs
Control of prostate growth.
Urology 1981;17(Suppl 3):17-24.
1981: John T Isaacs; Donald S Coffey
Changes in dihydrotestosterone metabolism associated with the development of canine benign prostatic hyperplasia.
Endocrinology 1981;108(2):445-53.
1981: John T Isaacs; Evelyn Barrack; William B Isaacs; Donald S Coffey
The relationship of cellular structure and function: the matrix system.
Progress in clinical and biological research 1981;75A():1-24.
1980: John T Isaacs; William B Isaacs; L G Wheaton; Donald S Coffey
Differential effects of estrogen treatment on canine seminal plasma components.
Investigative urology 1980;17(6):495-8.
1980: John T Isaacs; I R McDermott; Donald S Coffey
The identification and characterization of the C19O3 steroid metabolites of 5 alpha-androstane-3 beta,17 beta-diol produced by the canine prostate: 5 alpha-androstane-3 beta,6 alpha,17 beta-triol and 5 alpha-androstane-3 beta,7 alpha,17 beta-triol.
Steroids 1980;35(2):139-56.
1980: Donald S Coffey; John T Isaacs
Requirements for an idealized animal model of prostatic cancer.
Progress in clinical and biological research 1980;37():379-91.
1980: John T Isaacs; R M Weissman; Donald S Coffey; W W Scott
Concepts in prostatic cancer biology: Dunning R-3327 H, HI, and AT tumors.
Progress in clinical and biological research 1980;37():311-23.
1979: John T Isaacs; William B Isaacs; Donald S Coffey
Models for development of nonreceptor methods for distinguishing androgen-sensitive and -insensitive prostatic tumors.
Cancer research 1979;39(7 Pt 1):2652-9.
1979: John T Isaacs; I R McDermott; Donald S Coffey
The identification and characterization of a new C19O3 steroid metabolite in the rat ventral prostate: 5 alpha-androstane-3 beta, 6 alpha, 17 beta-triol.
Steroids 1979;33(6):639-57.
1979: John T Isaacs; I R McDermott; Donald S Coffey
Characterization of two new enzymatic activities of the rat ventral prostate: 5 alpha-androstane-3 beta, 17 beta-diol 6 alpha-hydroxylase and 5 alpha-androstane-3 beta, 17 beta-diol 7 alpha-hydroxylase.
Steroids 1979;33(6):675-92.
1979: John T Isaacs; W W Scott; Donald S Coffey
New biochemical methods to determine androgen sensitivity of prostatic cancer: the relative enzymatic index (REI).
Progress in clinical and biological research 1979;33():133-44.
1978: John T Isaacs; W D Heston; R M Weissman; Donald S Coffey
Animal models of the hormone-sensitive and -insensitive prostatic adenocarcinomas, Dunning R-3327-H, R-3327-HI, and R-3327-AT.
Cancer research 1978;38(11 Pt 2):4353-9.
1977: John T Isaacs; F Binkley
Cyclic AMP-dependent control of the rat hepatic glutathione disulfide-sulfhydryl ratio.
Biochimica et biophysica acta 1977;498(1):29-38.
1977: John T Isaacs; F Binkley
Glutathione dependent control of protein disulfide-sulfhydryl content by subcellular fractions of hepatic tissue.
Biochimica et biophysica acta 1977;497(1):192-204.